

ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplants, Vaccine Development), End User (Hospitals & Clinical Labs, Research Institutes) - Global Forecast to 2027

Market Report | 2022-10-31 | 187 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global ELISpot and FluoroSpot Assays market size is projected to reach USD 390 million by 2027 from USD 274 million in 2022, at a CAGR of 7.3% during the forecast period. Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries. On the other hand, availability of alternative detection technologies is expected to limit market growth to a certain extent in the coming years.

"The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product' market, during the forecast period"

The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products. In 2021, kits accounted for a sizable market share because they offer advantages in terms of high specificity and sensitivity and better detection limits as compared to other assays such as ELISA as well as their wide applications in the field of research and diagnostics.

"Diagnostic application segment accounted for the largest market share"

Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application. The Diagnostic application segment accounted for the largest market share in 2021., while research application is expected to grow at the fastest rate in the years ahead, from 2022 to 2027 considering their practice in several research applications, such as vaccine development, clinical trials, and cancer research.

"APAC region accounted for the highest CAGR"

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a significant market share in 2021 and the future. The Asia-Pacific market is being propelled by an increase in non-communicable (NCD), research funding on vaccines and changing disease profiles. North America, on the other hand, will experience significant growth in the coming years due to the presence of key players, the availability of technologically advanced ELISpot and FluoroSpot assay kits and analyzers.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World - 12%

Lits of Companies Profiled in the Report:

- Oxford Immunotec (UK)
- Cellular Technology Limited (US)
- Mabtech (Sweden)
- Becton, Dickinson and Company (US)
- Abcam plc. (UK)
- Bio-Techne. (US)
- Mikrogen Diagnostik (Germany)
- Autoimmun Diagnostika GmbH (Germany)
- U-CyTech (Netherland)
- Medix Biochemica (Finland)
- Merck KGaA (Germany)
- Bio-Sys GmbH (Germany)
- Anogen-Yes Biotech Laboratories Ltd (Canada)
- Abnova Corporation. (Taiwan)
- Biorbyt Ltd (UK)

Research Coverage:

This report studies the ELISpot and FluoroSpot Assays market based on product, applications, End user, and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total ELISpot and FluoroSpot Assays market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on ELISpot and FluoroSpot assay products offered by the top 25 players in the market. The report analyses the ELISpot and FluoroSpot Assays market by product, application, end user and region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the ELISpot and FluoroSpot Assays market

Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the ELISpot and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FluoroSpot Assays market
Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

Table of Contents:

1 INTRODUCTION 26

1.1 STUDY OBJECTIVES 26

1.2 MARKET DEFINITION 26

1.2.1 INCLUSIONS AND EXCLUSIONS 27

1.3 MARKET SCOPE 28

1.3.1 GEOGRAPHIC SCOPE 28

1.3.2 YEARS CONSIDERED 29

1.4 CURRENCY 29

1.5 LIMITATIONS 29

1.6 MARKET STAKEHOLDERS 30

1.7 SUMMARY OF CHANGES 30

2 RESEARCH METHODOLOGY 31

2.1 RESEARCH DATA 31

FIGURE 1 RESEARCH DESIGN 31

2.1.1 SECONDARY DATA 32

2.1.1.1 Secondary sources 32

2.1.2 PRIMARY DATA 33

FIGURE 2 PRIMARY SOURCES 33

2.1.2.1 Key data from primary sources 34

2.1.2.2 Key industry insights 35

2.1.2.3 Breakdown of primary interviews 35

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 35

FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 36

2.2 MARKET SIZE ESTIMATION 36

FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: OXFORD IMMUNOTEC (US) 37

FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 37

2.2.1 GROWTH FORECAST 38

FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38

FIGURE 8 TOP-DOWN APPROACH 39

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 40

FIGURE 9 DATA TRIANGULATION METHODOLOGY 40

2.4 MARKET SHARE ANALYSIS 41

2.5 STUDY ASSUMPTIONS 41

2.6 RISK ASSESSMENT 41

TABLE 1 RISK ASSESSMENT 41

?

3 EXECUTIVE SUMMARY 42

FIGURE 10 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 42

FIGURE 11 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 43

FIGURE 12 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 43

FIGURE 13 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION) 44

4 PREMIUM INSIGHTS 45

4.1	ELISPOT AND FLUOROSPOT ASSAYS MARKET OVERVIEW	45
FIGURE 14	RIISING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET	45
4.2	ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2022-2027	45
FIGURE 15	ELISPOT ASSAY KITS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD	45
4.3	NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT AND COUNTRY (2022)	46
FIGURE 16	ASSAYS KITS SEGMENT TO DOMINATE NORTH AMERICAN ELISPOT AND FLUOROSPOT ASSAYS MARKET IN 2022	46
4.4	ELISPOT AND FLUOROSPOT ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	47
FIGURE 17	ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH FROM 2022 TO 2027	47
5	MARKET OVERVIEW	48
5.1	INTRODUCTION	48
5.2	MARKET DYNAMICS	48
FIGURE 18	ELISPOT AND FLUOROSPOT ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	48
5.2.1	DRIVERS	49
5.2.1.1	Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis	49
FIGURE 19	INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)	49
TABLE 2	GLOBAL INCIDENCE OF INFECTIOUS DISEASES	50
5.2.1.2	Increasing vaccine development to address challenges of antimicrobial resistance	50
5.2.1.3	Increasing use of ELISpot and FluoroSpot assays in oncology	51
TABLE 3	INCIDENCE OF CANCER IN MEN, 2020	52
TABLE 4	INCIDENCE OF CANCER IN WOMEN, 2020	52
5.2.1.4	ELISpot assays as diagnostic tool in drug hypersensitivity reaction	53
TABLE 5	EXAMPLES OF ELISPOT ASSAYS IN DRUG HYPERSENSITIVITY REACTIONS	53
5.2.1.5	Growth in biotechnology and biopharmaceutical industries	54
5.2.2	OPPORTUNITIES	54
5.2.2.1	Use of FluoroSpot assays for multiple-analyte detection in single well	54
5.2.2.2	Growth opportunities in emerging economies	55
FIGURE 20	HEALTHCARE EXPENDITURE PER CAPITA IN BRIC COUNTRIES, 2012-2019	56
5.2.3	CHALLENGES	56
5.2.3.1	Availability of alternative detection technologies	56
5.2.3.2	Dearth of skilled professionals	56
5.2.4	RESTRAINTS	57
5.2.4.1	Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables	57
5.3	RANGES/SCENARIOS	58
FIGURE 21	PESSIMISTIC SCENARIO	58
FIGURE 22	OPTIMISTIC SCENARIO	58
FIGURE 23	REALISTIC SCENARIO	59
5.4	VALUE CHAIN ANALYSIS	59
FIGURE 24	VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES	59
5.5	SUPPLY CHAIN ANALYSIS	60
FIGURE 25	DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES	61
5.6	TECHNOLOGY ANALYSIS	61
5.7	PORTER'S FIVE FORCES ANALYSIS	62
5.7.1	THREAT OF NEW ENTRANTS	62
5.7.2	INTENSITY OF COMPETITIVE RIVALRY	62
5.7.3	BARGAINING POWER OF BUYERS	62
5.7.4	BARGAINING POWER OF SUPPLIERS	62
5.7.5	THREAT OF SUBSTITUTES	62

5.8	KEY STAKEHOLDERS AND BUYING CRITERIA	63
5.8.1	KEY STAKEHOLDERS IN BUYING PROCESS	63
FIGURE 26	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS	63
TABLE 6	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)	63
5.8.2	BUYING CRITERIA	63
FIGURE 27	KEY BUYING CRITERIA FOR TOP THREE END USERS	63
TABLE 7	KEY BUYING CRITERIA FOR TOP THREE END USERS	64
5.9	REGULATORY LANDSCAPE	64
TABLE 8	REGULATORY AUTHORITIES GOVERNING ELISPOT AND FLUOROSPOT ASSAYS MARKET	64
5.9.1	US	65
TABLE 9	US: CLASSIFICATION OF ELISPOT AND FLUOROSPOT ASSAY PRODUCTS	65
FIGURE 28	US: REGULATORY PROCESS FOR IVD DEVICES	66
5.9.2	CANADA	67
FIGURE 29	CANADA: REGULATORY PROCESS FOR IVD DEVICES	67
5.9.3	EUROPE	67
TABLE 10	EUROPE: CLASSIFICATION OF IVD DEVICES	68
5.9.4	JAPAN	69
FIGURE 30	JAPAN: REGULATORY PROCESS FOR IVD DEVICES	69
TABLE 11	JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	69
5.9.5	CHINA	70
TABLE 12	CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	70
5.9.6	INDIA	71
FIGURE 31	INDIA: REGULATORY PROCESS FOR IVD DEVICES	71
5.9.7	RUSSIA	71
TABLE 13	RUSSIA: CLASSIFICATION OF IVD DEVICES	71
5.9.8	SAUDI ARABIA	72
TABLE 14	SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	72
5.9.9	MEXICO	72
FIGURE 32	MEXICO: REGULATORY PROCESS FOR IVD DEVICES	72
TABLE 15	MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	73
5.9.10	BRAZIL	74
FIGURE 33	BRAZIL: REGULATORY PROCESS FOR IVD DEVICES	74
5.9.11	SOUTH KOREA	74
TABLE 16	SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	74
5.9.12	MIDDLE EAST	75
5.9.13	AFRICA	75
5.10	KEY CONFERENCES AND EVENTS IN 2022 AND 2023	75
TABLE 17	LIST OF CONFERENCES AND EVENTS	75
5.11	PATENT ANALYSIS	76
5.12	PRICING ANALYSIS	77
TABLE 18	ELISPOT AND FLUOROSPOT ASSAYS MARKET: PRICE RANGE FOR ELISPOT AND FLUOROSPOT ASSAY PRODUCTS	77
5.13	TRADE ANALYSIS	77
5.13.1	TRADE ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS	77
TABLE 19	IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017-2021 (USD MILLION)	78
TABLE 20	EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017-2021 (USD MILLION)	78
5.14	ECOSYSTEM ANALYSIS	78
5.14.1	ROLE IN ECOSYSTEM	79

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 34 KEY PLAYERS OPERATING IN ELISPOT AND FLUOROSPOT ASSAYS MARKET 79

5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 80

6 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT 81

6.1 INTRODUCTION 82

TABLE 21 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 82

6.2 ASSAY KITS 82

TABLE 22 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020-2027 (USD MILLION) 83

6.2.1 ASSAY KITS MARKET, BY TECHNIQUE 83

TABLE 23 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2020-2027 (USD MILLION) 83

6.2.1.1 ELISpot assay kits 83

6.2.1.1.1 Need for highly sensitive immune monitoring requirements in clinical trials to drive market 83

TABLE 24 ELISPOT ASSAY KITS MARKET, BY REGION, 2020-2027 (USD MILLION) 84

6.2.1.2 FluoroSpot assay kits 84

6.2.1.2.1 Increasing demand for multiple analyte detection and technological advancements to support market growth 84

TABLE 25 FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020-2027 (USD MILLION) 84

6.2.2 ASSAY KITS MARKET, BY UTILITY 85

TABLE 26 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY UTILITY, 2020-2027 (USD MILLION) 85

6.2.2.1 Diagnostic kits 85

6.2.2.1.1 Used for detection of infectious and autoimmune diseases 85

TABLE 27 DIAGNOSTIC KITS MARKET, BY REGION, 2020-2027 (USD MILLION) 85

6.2.2.2 Research kits 86

6.2.2.2.1 Continued investment in vaccine research, clinical trials, and cancer research to drive market 86

TABLE 28 RESEARCH KITS MARKET, BY REGION, 2020-2027 (USD MILLION) 86

6.2.3 ASSAY KITS MARKET, BY ANALYTE 86

TABLE 29 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY ANALYTE, 2020-2027 (USD MILLION) 86

6.2.3.1 T-cell-based kits 87

6.2.3.1.1 Low concentrations of infection-released analytes necessitate use of T-cell-based kits 87

TABLE 30 T-CELL-BASED KITS MARKET, BY REGION, 2020-2027 (USD MILLION) 87

6.2.3.2 B-cell-based kits 87

6.2.3.2.1 Detection of B-cell-based antibodies useful to study cell response post-infection/vaccination 87

TABLE 31 B-CELL-BASED KITS MARKET, BY REGION, 2020-2027 (USD MILLION) 87

6.2.3.3 Other analyte kits 88

TABLE 32 OTHER ANALYTE KITS MARKET, BY REGION, 2020-2027 (USD MILLION) 88

6.3 ANALYZERS 88

6.3.1 ADOPTION OF ASSAY KITS TO DRIVE USE OF ANALYZERS 88

TABLE 33 ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY REGION, 2020-2027 (USD MILLION) 88

6.4 ANCILLARY PRODUCTS 89

6.4.1 MARKET PLAYERS SUCH AS THERMO FISHER SCIENTIFIC PROVIDE ANCILLARY PRODUCTS 89

TABLE 34 ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY REGION, 2020-2027 (USD MILLION) 89

?

7 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION 90

7.1 INTRODUCTION 91

TABLE 35 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 91

7.2 DIAGNOSTIC APPLICATIONS 91

TABLE 36 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 91

TABLE 37 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 92

7.2.1 INFECTIOUS DISEASES 92

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2.1.1 Infectious diseases segment dominates diagnostic applications market 92

FIGURE 35 US: TOTAL CASES OF TICKBORNE DISEASES, 2004-2019 92

TABLE 38 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2027 (USD MILLION) 93

7.2.2 TRANSPLANTS 93

7.2.2.1 Growing incidence of infections caused during transplant procedures to drive demand for ELISpot and FluoroSpot assays 93

TABLE 39 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY REGION, 2020-2027 (USD MILLION) 93

7.3 RESEARCH APPLICATIONS 94

TABLE 40 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION) 94

TABLE 41 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 94

7.3.1 VACCINE DEVELOPMENT 94

7.3.1.1 Largest and fastest-growing segment of market 94

TABLE 42 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2020-2027 (USD MILLION) 95

7.3.2 CLINICAL TRIALS 95

7.3.2.1 Growing number of clinical trials to drive demand for ELISpot and FluoroSpot assays 95

FIGURE 36 NUMBER OF CLINICAL TRIALS, BY REGION, 2010-2021 95

TABLE 43 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY REGION, 2020-2027 (USD MILLION) 96

7.3.3 CANCER RESEARCH 96

7.3.3.1 Rising prevalence of cancer to support market growth 96

TABLE 44 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY REGION, 2020-2027 (USD MILLION) 97

8 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER 98

8.1 INTRODUCTION 99

TABLE 45 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 99

8.2 HOSPITAL AND CLINICAL LABORATORIES 99

8.2.1 LARGEST END USERS OF ELISPOT AND FLUOROSPOT ASSAYS 99

TABLE 46 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY REGION, 2020-2027 (USD MILLION) 100

8.3 RESEARCH INSTITUTES 100

8.3.1 FASTEST-GROWING END USERS OF ELISPOT AND FLUOROSPOT ASSAYS 100

TABLE 47 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION) 100

8.4 BIOPHARMACEUTICAL COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 101

8.4.1 BIOPHARMACEUTICAL COMPANIES AND CROs USE ELISPOT AND FLUOROSPOT ASSAYS FOR VACCINE DEVELOPMENT, CLINICAL TRIALS, AND CANCER RESEARCH 101

TABLE 48 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROs, BY REGION, 2020-2027 (USD MILLION) 102

9 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION 103

9.1 INTRODUCTION 104

TABLE 49 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION) 104

9.2 NORTH AMERICA 104

FIGURE 37 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT 105

TABLE 50 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 105

TABLE 51 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 106

TABLE 52 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 106

TABLE 53 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 106

9.2.1 US 107

9.2.1.1 US dominates North American ELISpot and FluoroSpot assays market 107

TABLE 54 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 107

TABLE 55 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 108

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 56 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 108

9.2.2 CANADA 108

9.2.2.1 High burden of chronic diseases and rising healthcare expenditure to drive adoption of ELISpot and FluoroSpot assays 108

TABLE 57 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 109

TABLE 58 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 110

TABLE 59 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 110

?

9.3 EUROPE 110

FIGURE 38 GLOBAL VACCINE PRODUCTION 111

TABLE 60 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 111

TABLE 61 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 112

TABLE 62 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 112

TABLE 63 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 112

9.3.1 GERMANY 113

9.3.1.1 Fastest-growing country in European ELISpot and FluoroSpot assays market 113

TABLE 64 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 113

TABLE 65 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 114

TABLE 66 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 114

9.3.2 UK 114

9.3.2.1 Rising prevalence of NCDs to drive market 114

TABLE 67 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 115

TABLE 68 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 115

TABLE 69 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 115

9.3.3 FRANCE 116

9.3.3.1 Need for early disease diagnosis to support market growth 116

TABLE 70 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 116

TABLE 71 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 116

TABLE 72 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 117

9.3.4 ITALY 117

9.3.4.1 Growing geriatric population and increasing support for research to support market 117

TABLE 73 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 118

TABLE 74 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 118

TABLE 75 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 118

9.3.5 SPAIN 119

9.3.5.1 High incidence of chronic diseases to drive market 119

TABLE 76 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 119

TABLE 77 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 120

TABLE 78 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 120

9.3.6 REST OF EUROPE 120

TABLE 79 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 121

TABLE 80 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 121

TABLE 81 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION) 121

9.4 ASIA PACIFIC 122

FIGURE 39 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT 122

TABLE 82 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 123

TABLE 83 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 123

TABLE 84 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 123

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 85	ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION)	124
9.4.1	CHINA	124
9.4.1.1	Rising focus on vaccine development and cancer research to drive market	124
TABLE 86	CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	125
TABLE 87	CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	125
TABLE 88	CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION)	125
9.4.2	JAPAN	126
9.4.2.1	Increased focus on vaccine research and rising prevalence of chronic diseases to drive market	126
TABLE 89	JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	126
TABLE 90	JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	127
TABLE 91	JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION)	127
9.4.3	INDIA	127
9.4.3.1	High incidence of chronic diseases and growing vaccine R&D activity to drive market	127
TABLE 92	INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	128
TABLE 93	INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	128
TABLE 94	INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION)	129
9.4.4	REST OF ASIA PACIFIC	129
TABLE 95	REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	130
TABLE 96	REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	130
TABLE 97	REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION)	130
9.5	REST OF THE WORLD	131
TABLE 98	REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	131
TABLE 99	REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	131
TABLE 100	REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020-2027 (USD MILLION)	131
10	COMPETITIVE LANDSCAPE	132
10.1	OVERVIEW	132
10.2	STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN	132
TABLE 101	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET	132
10.3	REVENUE SHARE ANALYSIS	133
FIGURE 40	REVENUE ANALYSIS OF KEY PUBLIC PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET	133
10.4	MARKET SHARE ANALYSIS	133
TABLE 102	ELISPOT AND FLUOROSPOT ASSAYS MARKET: DEGREE OF COMPETITION	133
10.5	COMPANY EVALUATION QUADRANT	134
10.5.1	STARS	135
10.5.2	EMERGING LEADERS	135
10.5.3	PERVASIVE PLAYERS	135
10.5.4	PARTICIPANTS	135
FIGURE 41	COMPANY EVALUATION QUADRANT: ELISPOT AND FLUOROSPOT ASSAYS MARKET, 2021	136
10.6	COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS	137
10.6.1	PROGRESSIVE COMPANIES	137
10.6.2	STARTING BLOCKS	137
10.6.3	RESPONSIVE COMPANIES	137
10.6.4	DYNAMIC COMPANIES	137
FIGURE 42	COMPANY EVALUATION MATRIX FOR SMES/STARTUPS: ELISPOT AND FLUOROSPOT ASSAYS MARKET, 2021	138
10.7	FOOTPRINT ANALYSIS OF COMPANIES	139
TABLE 103	FOOTPRINT ANALYSIS OF COMPANIES	139
TABLE 104	PRODUCT FOOTPRINT OF COMPANIES	140

TABLE 105	REGIONAL FOOTPRINT OF COMPANIES	141
?		
10.8	COMPETITIVE BENCHMARKING	142
TABLE 106	ELISPOT AND FLUOROSPOT ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES	142
10.9	COMPETITIVE SCENARIO	142
10.9.1	PRODUCT LAUNCHES	142
TABLE 107	KEY PRODUCT LAUNCHES	142
10.9.2	DEALS	143
TABLE 108	KEY DEALS	143
10.9.3	OTHER DEVELOPMENTS	143
TABLE 109	OTHER KEY DEVELOPMENTS	143
11	COMPANY PROFILES	144
11.1	KEY PLAYERS	144
(Business Overview, Products Offered, Recent Developments, and MnM View)*		
11.1.1	OXFORD IMMUNOTEC LTD. (SUBSIDIARY OF PERKINELMER, INC.)	144
TABLE 110	OXFORD IMMUNOTEC LTD.: BUSINESS OVERVIEW	144
FIGURE 43	OXFORD IMMUNOTEC LTD. (SUBSIDIARY OF PERKINELMER, INC.): COMPANY SNAPSHOT (2022)	145
11.1.2	BECTON, DICKINSON AND COMPANY	147
TABLE 111	BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW	147
FIGURE 44	BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)	148
11.1.3	CELLULAR TECHNOLOGY LIMITED	151
TABLE 112	CELLULAR TECHNOLOGY LIMITED: BUSINESS OVERVIEW	151
11.1.4	MABTECH	153
TABLE 113	MABTECH: BUSINESS OVERVIEW	153
11.1.5	ABCAM PLC	155
TABLE 114	ABCAM PLC: BUSINESS OVERVIEW	155
FIGURE 45	ABCAM PLC: COMPANY SNAPSHOT (2021)	156
11.1.6	BIO-TECHNE	157
TABLE 115	BIO-TECHNE: BUSINESS OVERVIEW	157
FIGURE 46	BIO-TECHNE: COMPANY SNAPSHOT (2022)	158
11.1.7	MERCK KGAA	160
TABLE 116	MERCK KGAA: BUSINESS OVERVIEW	160
FIGURE 47	MERCK KGAA: COMPANY SNAPSHOT (2021)	161
11.1.8	AUTOIMMUN DIAGNOSTIKA GMBH	163
TABLE 117	AUTOIMMUN DIAGNOSTIKA GMBH: BUSINESS OVERVIEW	163
11.1.9	U-CYTECH	164
TABLE 118	U-CYTECH: BUSINESS OVERVIEW	164
11.1.10	MIKROGEN DIAGNOSTIK	166
TABLE 119	MIKROGEN DIAGNOSTIK: BUSINESS OVERVIEW	166
11.1.11	MEDIX BIOCHEMICA	167
TABLE 120	MEDIX BIOCHEMICA: BUSINESS OVERVIEW	167
11.1.12	ABNOVA CORPORATION	169
TABLE 121	ABNOVA CORPORATION: BUSINESS OVERVIEW	169
11.1.13	ANOGEN-YES BIOTECH LABORATORIES LTD.	170
TABLE 122	ANOGEN-YES BIOTECH LABORATORIES LTD.: BUSINESS OVERVIEW	170
11.1.14	BIORBYT LTD.	171
TABLE 123	BIORBYT LTD.: BUSINESS OVERVIEW	171

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1.15	BIO-SYS GMBH	173
TABLE 124	BIO-SYS GMBH: BUSINESS OVERVIEW	173
11.2	OTHER PLAYERS	174
11.2.1	JACKSON IMMUNORESEARCH INC.	174
TABLE 125	JACKSON IMMUNORESEARCH INC.: BUSINESS OVERVIEW	174
11.2.2	IST SCIENTIFIC LTD.	175
TABLE 126	IST SCIENTIFIC LTD.: BUSINESS OVERVIEW	175
11.2.3	SERVA ELECTROPHORESIS GMBH	176
TABLE 127	SERVA ELECTROPHORESIS GMBH: BUSINESS OVERVIEW	176
11.2.4	KRISHGEN BIOSYSTEMS	177
TABLE 128	KRISHGEN BIOSYSTEMS: BUSINESS OVERVIEW	177
11.2.5	NATIONAL ANALYTICAL CORPORATION	178
TABLE 129	NATIONAL ANALYTICAL CORPORATION: BUSINESS OVERVIEW	178
11.2.6	STEMCELL TECHNOLOGIES INC.	179
TABLE 130	STEMCELL TECHNOLOGIES INC.: BUSINESS OVERVIEW	179
11.2.7	ZENBIO, INC.	180
TABLE 131	ZENBIO, INC.: BUSINESS OVERVIEW	180
11.2.8	BOC SCIENCES	181
TABLE 132	BOC SCIENCES: BUSINESS OVERVIEW	181
11.2.9	TOKYO CHEMICAL INDUSTRY CO., LTD.	182
TABLE 133	TOKYO CHEMICAL INDUSTRY CO., LTD.: BUSINESS OVERVIEW	182
11.2.10	MP BIOMEDICALS	183
TABLE 134	MP BIOMEDICALS: BUSINESS OVERVIEW	183
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.		
12	APPENDIX	184
12.1	INDUSTRY INSIGHTS	184
12.2	DISCUSSION GUIDE	185
12.3	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	189
12.4	CUSTOMIZATION OPTIONS	191
12.5	RELATED REPORTS	191
12.6	AUTHOR DETAILS	192

ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplants, Vaccine Development), End User (Hospitals & Clinical Labs, Research Institutes) - Global Forecast to 2027

Market Report | 2022-10-31 | 187 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-21

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com